Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States

Cromer, Barbara A.; Berg-Kelly, Kristina; Groningen, J. P.; Seimer, Belinda S; Ruusuvaara, L

doi:10.1016/s1054-139x(98)00030-5

Cited by 17 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cross-sectional (3,7,(11)(12)(13)(14)(15)(16)(17)(18) and longitudinal (19 -21) studies have indicated that the use of DMPA may have adverse effects on bone metabolism, resulting in impaired bone mineral acquisition during adolescence and accelerated bone loss in adult life. The findings of this large, population-based case-control analysis provide further evidence that current or past use of DMPA may be associated with an increased risk of fractures in women between the age of 20 and the perimenopausal period.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast to estrogen-containing oral contraceptives, which do not appear to have negative effects on biochemical markers of bone turnover or bone mineral density (BMD) (6), use of DMPA has been associated with accelerated bone turnover (7)(8)(9)(10) and with a decline in BMD (3,7,(11)(12)(13)(14)(15)(16)(17)(18). Cross-sectional studies have described BMD deficits ranging from 2.5-18% at the lumbar spine and from 2.2-17% at the proximal femur (18).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

Meier¹,

Brauchli²,

Jick³

et al. 2010

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

Meier¹,

Brauchli²,

Jick³

et al. 2010

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

show abstract

“…This age group was chosen to coincide with age ranges used in other studies of adolescent contraceptive use and compliance [1,12]. Additionally, this is the age range for which oral contraceptives are most popular [4,5,13].…”

Section: Study Populationmentioning

confidence: 99%

An evaluation of the use of the transdermal contraceptive patch in adolescents

Rubinstein

Halpern‐Felsher

Irwin

2004

Journal of Adolescent Health

View full text Add to dashboard Cite

“…Many clinicians recommend prescribing MPA instead of oral contraceptives specifically for adolescent patients to avoid compliance issues associated with a daily pill regimen (Cromer et al 1998, Khoiny 1996, Tolaymat & Kaunitz 2007. Between 2006 and 2008, over 270 000 adolescent girls (ages 15-19) in the United States alone were using MPA (Mosher & Jones 2010).…”

Section: Introductionmentioning

confidence: 99%

Early adolescent Depo-Provera exposure increases stillbirths in adult sooty mangabeys

Cappelletti¹,

Ethun²,

Meeker³

et al. 2015

Reproduction

View full text Add to dashboard Cite

The 3-month injectable contraceptive medroxyprogesterone acetate (MPA; Depo-Provera) is a synthetic progestin that protects against pregnancy by suppressing ovulation. Studies have focused on the resumption of ovulation after MPA-treatment cessation but neglected potential long-term effects of MPA exposure on future successful reproduction. MPA is frequently administered to adolescent girls; however, long-term fertility effects of adolescent MPA exposure have not been explored. We investigated fertility after extended MPA exposure in a species of old world primate, the sooty mangabey (Cercocebus atys). Female sooty mangabeys (nZ31) received chronic MPA-treatment for 4-8 years. At MPA-treatment onset, subjects were either parous adults (nZ14) or nulliparous adolescents (nZ17), with adolescent-treated subjects being further divided into those who had reached first ovulation (nZ10) and those who had not (nZ7). After MPA-treatment cessation, adolescent-treated females had a significantly higher incidence of stillbirth than did age-matched and parity-matched controls, whereas adult-treated females did not differ from their matched controls. Females placed on MPA-treatment prior to first ovulation had a significantly higher incidence of stillbirth post-treatment than did females placed on MPA-treatment after first ovulation. Diabetic females had an increased incidence of stillbirth as compared to nondiabetic females; however, when controlling for diabetes, MPA exposure prior to first ovulation was still a significant positive predictor of stillbirth. These findings suggest that the post-treatment fertility effects of chronic MPA exposure vary with the developmental timing of treatment onset and raise concern about the use of MPA as a contraceptive for adolescent girls.Reproduction (2015) 150 497-505

show abstract

Depot medroxyprogesterone acetate (Depo-Provera) and levonorgestrel (Norplant) use in adolescents among clinicians in Northern Europe and the United States

Cited by 17 publications

References 11 publications

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

Use of Depot Medroxyprogesterone Acetate and Fracture Risk

An evaluation of the use of the transdermal contraceptive patch in adolescents

Early adolescent Depo-Provera exposure increases stillbirths in adult sooty mangabeys

Contact Info

Product

Resources

About